These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 18175273)

  • 21. Can positron emission tomography facilitate paediatric drug development?
    Zimmer L
    Fundam Clin Pharmacol; 2008 Dec; 22(6):595-8. PubMed ID: 19049660
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantitative pharmacology or pharmacokinetic pharmacodynamic integration should be a vital component in integrative pharmacology.
    Gabrielsson J; Green AR
    J Pharmacol Exp Ther; 2009 Dec; 331(3):767-74. PubMed ID: 19779129
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [New methods of dose optimization and individualized pharmacotherapy? Determination of drug concentration and pharmacokinetic analysis at the site. I].
    Schäftlein A; Simmel F; Kloft C
    Med Monatsschr Pharm; 2013 Mar; 36(3):97-101. PubMed ID: 23573692
    [No Abstract]   [Full Text] [Related]  

  • 24. Positron emission tomography/computed tomography: the current technology and applications.
    Mittra E; Quon A
    Radiol Clin North Am; 2009 Jan; 47(1):147-60. PubMed ID: 19195540
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [PET as a tool in pharmacologic development].
    Bergström M; Hartvig P; Långström B
    Nord Med; 1998 Sep; 113(7):226-9. PubMed ID: 9755618
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: strategic considerations.
    Gabrielsson J; Dolgos H; Gillberg PG; Bredberg U; Benthem B; Duker G
    Drug Discov Today; 2009 Apr; 14(7-8):358-72. PubMed ID: 19162219
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Less is more: the human microdosing concept.
    Garner RC
    Drug Discov Today; 2005 Apr; 10(7):449-51. PubMed ID: 15809185
    [No Abstract]   [Full Text] [Related]  

  • 28. The dose makes the medicine.
    Stumpf WE
    Drug Discov Today; 2006 Jun; 11(11-12):550-5. PubMed ID: 16713907
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiac positron emission tomography.
    Bengel FM; Higuchi T; Javadi MS; Lautamäki R
    J Am Coll Cardiol; 2009 Jun; 54(1):1-15. PubMed ID: 19555834
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PET & SPECT instrumentation.
    Spanoudaki VC; Ziegler SI
    Handb Exp Pharmacol; 2008; (185 Pt 1):53-74. PubMed ID: 18626798
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of the Hsp90 inhibitor NVP-AUY922 in multicellular tumour spheroids with respect to effects on growth and PET tracer uptake.
    Monazzam A; Razifar P; Ide S; Rugaard Jensen M; Josephsson R; Blomqvist C; Langström B; Bergström M
    Nucl Med Biol; 2009 Apr; 36(3):335-42. PubMed ID: 19324279
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Application of PET/CT in the development of novel anticancer drugs.
    Boss DS; Olmos RV; Sinaasappel M; Beijnen JH; Schellens JH
    Oncologist; 2008 Jan; 13(1):25-38. PubMed ID: 18245010
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Molecular imaging for drug development].
    Watanabe Y
    Brain Nerve; 2007 Mar; 59(3):209-14. PubMed ID: 17370646
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fast high performance liquid chromatography in PET quality control and metabolite analysis.
    Passchier J
    Q J Nucl Med Mol Imaging; 2009 Aug; 53(4):411-6. PubMed ID: 19834451
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Microdosing: the new pharmacokinetic paradigm?
    Zanni GR; Wick JY
    Consult Pharm; 2006 Oct; 21(10):756-76. PubMed ID: 17243857
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PET/CT for the staging and follow-up of patients with malignancies.
    Poeppel TD; Krause BJ; Heusner TA; Boy C; Bockisch A; Antoch G
    Eur J Radiol; 2009 Jun; 70(3):382-92. PubMed ID: 19406595
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Medical imaging in pharmaceutical clinical trials: what radiologists should know.
    Wang YX
    Clin Radiol; 2005 Oct; 60(10):1051-7. PubMed ID: 16179164
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Practical experience of using human microdosing with AMS analysis to obtain early human drug metabolism and PK data.
    Garner RC
    Bioanalysis; 2010 Mar; 2(3):429-40. PubMed ID: 21083253
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Microdosing and drug development: past, present and future.
    Lappin G; Noveck R; Burt T
    Expert Opin Drug Metab Toxicol; 2013 Jul; 9(7):817-34. PubMed ID: 23550938
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design, synthesis, and binding affinities of potential positron emission tomography (PET) ligands with optimal lipophilicity for brain imaging of the dopamine D3 receptor. Part II.
    Leopoldo M; Lacivita E; De Giorgio P; Contino M; Berardi F; Perrone R
    Bioorg Med Chem; 2009 Jan; 17(2):758-66. PubMed ID: 19081257
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.